Last reviewed · How we verify

Biosone — Competitive Intelligence Brief

Biosone (ENOXOLONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: enoxolone. Area: Nephrology.

phase 2 enoxolone High mobility group protein B1, Aldo-keto reductase family 1 member B10, Cocaine esterase Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Biosone (ENOXOLONE). Biosone works by blocking the enzyme that converts cortisol into cortisone, reducing inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Biosone TARGET ENOXOLONE phase 2 enoxolone High mobility group protein B1, Aldo-keto reductase family 1 member B10, Cocaine esterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (enoxolone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biosone — Competitive Intelligence Brief. https://druglandscape.com/ci/enoxolone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing